Literature DB >> 31395488

Increased risk of smoking-related illnesses in schizophrenia patients: A nationwide cohort study.

Israel Krieger1, Dana Tzur Bitan2, Doron Comaneshter3, Arnon Cohen4, Daniel Feingold5.   

Abstract

BACKGROUND: Schizophrenia patients smoke at three times the rate of the general population, and are more susceptible to smoking-related illnesses. The goal of the current study was to evaluate the cumulative probability of chronic obstructive pulmonary disease (COPD) and ischemic heart disease (IHD) following first documentation of smoking among schizophrenia patients as compared to smoking healthy controls.
METHODS: A nationally representative cohort study was designed to assess the odds and cumulative probability of COPD and IHD among individuals with schizophrenia (n = 10,502) and a matched-sample of smoking healthy controls (n = 10,502). Hierarchical logistic regressions and Kaplan-Meier regression models were used to compare odds and cumulative probabilities across the two groups.
RESULTS: After adjusting for clinical and demographic factors, smoking schizophrenia patients had a higher probability of receiving a diagnosis of COPD than smoking healthy controls (OR 2.14, 95%CI 1.51-3.01, p < 0.001). The probability of having COPD increased more rapidly in smoking schizophrenia patients, yet the opposite trajectory prevailed for IHD, showing a decreased cumulative probability in smoking schizophrenia patients compared to smoking healthy controls. DISCUSSION: Schizophrenia has a unique contribution to the facilitation of COPD, which extends beyond the effect of smoking, or other clinical and demographic risk factors. Differential smoking patterns could potentially account for this effect. The differential pattern of IHD should be subjected to further research, as our results might indicate that schizophrenia patients are underdiagnosed with IHD, and may be even less diagnosed as a function of time and chronicity.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Ischemic heart disease; Schizophrenia; Smoking

Mesh:

Year:  2019        PMID: 31395488     DOI: 10.1016/j.schres.2019.07.058

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking.

Authors:  M J Jaen-Moreno; N Feu; G I Del Pozo; C Gómez; L Carrión; G M Chauca; I Guler; F J Montiel; M D Sánchez; J A Alcalá; L Gutierrez-Rojas; V Molina; J Bobes; V Balanzá-Martínez; C Ruiz-Rull; F Sarramea
Journal:  Eur Psychiatry       Date:  2021-02-26       Impact factor: 5.361

2.  Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment.

Authors:  Silvia Moga; Andreea Teodorescu; Petru Ifteni; Claudia Gavris; Paula-Simina Petric
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-02       Impact factor: 2.570

3.  Impaired long-term outcomes of patients with schizophrenia spectrum disorder after coronary artery bypass surgery: nationwide case-control study.

Authors:  Mika Kallio; Jyrki Korkeila; Markus Malmberg; Jarmo Gunn; Päivi Rautava; Päivi Korhonen; Ville Kytö
Journal:  BJPsych Open       Date:  2022-02-11

4.  Sudden cardiac arrest in patients with schizophrenia: A population-based study of resuscitation outcomes and pre-existing cardiovascular disease.

Authors:  Gabriel G Edwards; Audrey Uy-Evanado; Eric C Stecker; Angelo Salvucci; Jonathan Jui; Sumeet S Chugh; Kyndaron Reinier
Journal:  Int J Cardiol Heart Vasc       Date:  2022-04-08

5.  Severe breakthrough COVID-19 infections in vaccinated patients with schizophrenia in Israel.

Authors:  Dana Tzur Bitan; Noga Givon-Lavi; Khalaf Kridin; Ehud Kaliner; Israel Krieger; Arnon Dov Cohen; Orly Weinstein
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

6.  COVID-19 Morbidity Among Individuals with Autistic Spectrum Disorder: A Matched Controlled Population-Based Study.

Authors:  Israel Krieger; Galit Erez; Orly Weinstein; Arnon Dov Cohen; Dana Tzur Bitan
Journal:  J Autism Dev Disord       Date:  2021-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.